Skip to main content

Conclusions of the expert panel: importance of erlotinib as a second-line therapeutic option

Access & Citations

  • 3553
    Article Accesses
  • 0
    Web of Science
  • 1

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.